Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.44 |
| ▸ | STK17B | O94768 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418456 | 0.87 | STK17A (0.47) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5415948 | 0.83 | HDAC3 (0.49) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5415421 | 0.82 | STK17A (0.48) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5408198 | 0.82 | HDAC3 (0.48) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5413555 | 0.81 | HDAC3 (0.46) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5418427 | 0.81 | HDAC3 (0.47) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5410091 | 0.80 | APEX1 (0.53) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5416137 | 0.80 | HDAC3 (0.46) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5413822 | 0.80 | CYP3A4 (0.53) | STK17ASTK17BLRRK2JAK2HDAC1 | |
| SCHEMBL5408196 | 0.79 | MEN1 (0.54) | LRRK2JAK2HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | STK17A 3456/4885STK17B 3502/4885LRRK2 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.